Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis
NCT03401229
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
413
Enrollment
INDUSTRY
Sponsor class
Conditions
Nasal Polyposis
Interventions
BIOLOGICAL:
Benralizumab 30 mg SC + Mometasone Furoate
BIOLOGICAL:
Matching placebo SC + Mometasone Furoate
Sponsor
AstraZeneca